This led us to hypothesize that reductions in NTF2 expression might promote melanoma progression to more advanced stages of disease, motivating our current study to test if ectopic NTF2 expression in metastatic melanoma could abrogate certain cancer cell phenotypes. The gene discussed is NUTF2; the disease is cancer.